GLP-1 prescriptions for severe obesity have surged 300-fold from 2018 to 2025, now exceeding 1.4 million annually. UC San Diego researchers analysed 20 million patient records to document this pharmaceutical breakthrough.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Most severe obesity still goes untreated as GLP-1 use climbs and surgery slips
1.4 Million annual GLP-1 prescriptions 2025
4,600 annual GLP-1 prescriptions 2018
20 Million records Patient records analyzed
300x fold increase Growth rate
300x Increase growth since 2018